哪里想瘦打哪里！FDA批准Kythera注射抗生素上市在即

你才双下巴，你全家都双下巴！其实质大方不免人皆有之。如果说赘肉是每一个想要持有理想身材高大的“妹纸”或“汉纸”的大敌，那么一个出人意表十足的双下巴已是是这些人的生死背叛了。每一分钟，亚洲地区都有人为自己的一张大饼脸而感到烦恼，虽然持有一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的心理素质使其未能经受一个双下巴之重。您可千万别自嘲，这甚至已经催生出一个庞大的市场竞争。根据加拿大皮肤外科手术协会的实地调查学术研究标示出，68%的加拿大人对自己的双下巴表示了“沮丧”之情。而有鉴于此，早先Kythera新公司向FDA提交了其主要用途击垮双下巴的护肤注射式抑制剂ATX-101。这种抑制剂完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，已是是定点减肥。不要以为这种近乎天真的抑制剂只是一个自嘲话，在FDA辖下的皮肤和内科抑制剂专员会的无记名候选人中，专家可是以17：0的超高票一致赞同其港交所。或许是因为这些专家中也有很多饱受双下巴之苦吧。FDA也将构想于当年的5年初13日之前对其跟进最后决定。如果一切顺利的话，Kythera新公司构想于当年年初将该厂商港交所，归纳民间团体预计这一抑制剂的营业收入将高达3亿美元之多。随着护肤抑制剂市场竞争的日益增大，Kythera新公司已是是下了一步好棋。新公司于上次以8400万美元的价格从其前合作拜耳赶走出让了这种抑制剂的全部权利。而Kythera新公司也想要以此为契机在护肤抑制剂市场竞争中出城拔寨。就在上个年初，Kythera新公司和Actelion新公司达成效益2700万美元的合作备忘录，所设计一种失败过的抗炎症抑制剂，而这种抑制剂被视为也许开发出一种疗法脱发的抑制剂。简要全名报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.